arrow
M

Morana Vojnic

Rutgers Cancer Institute
H指数:12
被引数:859

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Intracranial manifestations of adult Rosai-Dorfman disease: a systematic review and IPD meta-analysis of 327 cases

成人Rosai-Dorfman病的颅内表现:一项系统综述和327例个体参与者数据(IPD)荟萃分析

2025-12-060
PRE
Superselective intra-arterial (IA) bevacizumab administration decreases venous thromboembolism (VTE) incidence compared to standard intravenous (IV) bevacizumab in glioblastoma multiforme (GBM)

超选择性动脉内(IA)贝伐珠单抗给药与标准静脉内(IV)贝伐珠单抗相比,可降低多形性胶质母细胞瘤(GBM)中静脉血栓栓塞(VTE)的发生率。

2025-11-010
OAAI
EARLY SAFETY DATA FROM A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY, VERSUS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA (NDGBM)
2024-11-110
PRE
EARLY SAFETY DATA FROM A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY, VERSUS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA
2024-10-170
PRE
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations (vol 4, pg 1345, 2023)
2023-10-091
OAAI
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
2023-09-2111
OAAI